Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
The Journal of Experimental Medicine|September 5, 2002
Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanomaTomohide Tatsumi, Lisa S Kierstead, Elena Ranieri, et al.
Journal of Endovascular Therapy : an Official Journal of the International Society of Endovascular Specialists|February 23, 2024
Rescue From Permanent Kidney Injury in Acute Thrombosis of Both Renal Veins, the Inferior Vena Cava, and Both Iliofemoral Veins by Catheter-Based ThrombectomyFelix Hofer, Jan Mueller, Dragan Copic, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2005
Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogsDik J Kwekkeboom, Jan Mueller-Brand, Giovanni Paganelli, et al.
Plos Biology|January 24, 2014
Electron tomography and simulation of baculovirus actin comet tails support a tethered filament model of pathogen propulsionJan Mueller, Julia Pfanzelter, Christoph Winkler, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|June 27, 2006
Liver transplantation for patients with metastatic endocrine tumors: single-center experience with 15 patientsAndrea Frilling, Massimo Malago, Frank Weber, et al.
The Oncologist|April 28, 2020
EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell LymphomaIrene Papadouli, Jan Mueller-Berghaus, Claire Beuneu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2006
Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance pStefan Kneifel, Dominik Cordier, Stephan Good, et al.
EMBO Molecular Medicine|February 14, 2024
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cellsJan Mueller, Roman R Schimmer, Christian Koch, et al.
Pageof 7